Can a reversal drug protect memory during ECT for depression?
NCT ID NCT07619092
First seen Jun 03, 2026 · Last updated Jun 24, 2026 · Updated 3 times
Summary
This study tests whether giving flumazenil, a drug that reverses the effects of benzodiazepines, right before electroconvulsive therapy (ECT) can reduce cognitive side effects like memory loss in hospitalized patients with depression. About 145 participants will either continue their benzodiazepine and receive flumazenil before ECT, or stop the benzodiazepine beforehand as usual. The goal is to see if flumazenil helps protect thinking and memory without reducing ECT's effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
RECRUITINGFrederiksberg, Capital Region, 2000, Denmark
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flumazenil
What this could lead to
If it works, this could offer a way to reduce memory and thinking side effects of ECT for depression, making the treatment easier to tolerate.
What could go wrong
This is a small, early-stage trial. The benefit may be small or not appear, and flumazenil could cause anxiety or other side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.